{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:22:50Z","timestamp":1790893370259,"version":"4.1.0"},"reference-count":328,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005849","name":"Baqiyatallah University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005849","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003969","name":"Ministry of Health and Medical Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jiph.2026.103264","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:56:07Z","timestamp":1779292567000},"page":"103264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Old drugs, new lifelines: An update on drug repurposing against multidrug-resistant Acinetobacter baumannii"],"prefix":"10.1016","volume":"19","author":[{"given":"Mohamad Abavi","family":"Saany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abolfazl","family":"Jahangiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2026.103264_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jiph.2026.103264_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12250-019-00125-0","article-title":"Specific and selective bacteriophages in the fight against multidrug-resistant Acinetobacter baumannii","volume":"34","author":"Bagi\u0144ska","year":"2019","journal-title":"Virol Sin"},{"key":"10.1016\/j.jiph.2026.103264_bib3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/jam.14135","article-title":"Specific egg yolk antibodies (IgY) confer protection against Acinetobacter baumannii in a murine pneumonia model","volume":"126","author":"Jahangiri","year":"2019","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib4","article-title":"Acinetobacter baumannii: an evolving and cunning opponent","volume":"15","author":"Shi","year":"2024","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib5","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1186\/s12879-021-06513-w","article-title":"Molecular study of metallo-\u03b2-lactamases and integrons in Acinetobacter baumannii isolates from burn patients","volume":"21","author":"Nikibakhsh","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12941-021-00480-5","article-title":"Prevalence of \u03b2-lactamase-encoding genes and molecular typing of Acinetobacter baumannii isolates carrying carbapenemase OXA-24 in children","volume":"20","author":"Yousefi Nojookambari","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jiph.2026.103264_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10030373","article-title":"Acinetobacter baumannii antibiotic resistance mechanisms","volume":"10","author":"Kyriakidis","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.jiph.2026.103264_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fcimb.2017.00055","article-title":"Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options","volume":"7","author":"Lee","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib9","doi-asserted-by":"crossref","first-page":"fnx048","DOI":"10.1093\/femsle\/fnx048","article-title":"Horizontal transfer of the bla NDM-1 gene to Pseudomonas aeruginosa and Acinetobacter baumannii in biofilms","volume":"364","author":"Tanner","year":"2017","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.jiph.2026.103264_bib10","doi-asserted-by":"crossref","first-page":"e1708","DOI":"10.1093\/milmed\/usac020","article-title":"Chronic wound infection model of Acinetobacter baumannii in outbred mice","volume":"188","author":"Ruamsap","year":"2023","journal-title":"Mil Med"},{"key":"10.1016\/j.jiph.2026.103264_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1134\/S1068162023020139","article-title":"Drug repurposing: an effective tool in modern drug discovery","volume":"49","author":"Kulkarni","year":"2023","journal-title":"Russ J Bioorg Chem"},{"key":"10.1016\/j.jiph.2026.103264_bib12","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1093\/jac\/dkq353","article-title":"Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii","volume":"65","author":"Chopra","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib13","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fcimb.2018.00438","article-title":"Repurposing screen identifies unconventional drugs with activity against multidrug resistant Acinetobacter baumannii","volume":"8","author":"Cheng","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00284-021-02693-5","article-title":"Can drug repurposing be effective against carbapenem-resistant Acinetobacter baumannii?","volume":"79","author":"Gontijo","year":"2021","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib15","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.2147\/IDR.S439241","article-title":"Risk factors, outcomes, and predictions of extensively drug-resistant Acinetobacter baumannii nosocomial infections in patients with nervous system diseases","author":"Huang","year":"2023","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiph.2026.103264_bib16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/apm.13061","article-title":"Prevention of nosocomial Acinetobacter baumannii infections with a conserved immunogenic fimbrial protein","volume":"128","author":"Mahmoudi","year":"2020","journal-title":"Apmis"},{"key":"10.1016\/j.jiph.2026.103264_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/2049-632X.12125","article-title":"Acinetobacter baumannii: evolution of a global pathogen","volume":"71","author":"Antunes","year":"2014","journal-title":"Pathog Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.793615","article-title":"Convergence of biofilm formation and antibiotic resistance in Acinetobacter baumannii infection","volume":"9","author":"Roy","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.jiph.2026.103264_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115583","article-title":"Passive immunization with anti-FimA egg yolk antibodies (IgYs) mitigate Acinetobacter baumannii pneumonia in mice","volume":"167","author":"Shaygankho","year":"2023","journal-title":"Biomed & Pharmacother"},{"key":"10.1016\/j.jiph.2026.103264_bib20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1574-695X.2011.00818.x","article-title":"Biofilm formation by Acinetobacter baumannii strains isolated from urinary tract infection and urinary catheters","volume":"62","author":"Pour","year":"2011","journal-title":"FEMS Immunol & Med Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s43094-023-00525-w","article-title":"Acinetobacter baumannii biofilm and its potential therapeutic targets","volume":"9","author":"Mohamed","year":"2023","journal-title":"Future J Pharm Sci"},{"key":"10.1016\/j.jiph.2026.103264_bib22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13756-023-01343-8","article-title":"Acinetobacter baumannii: assessing susceptibility patterns, management practices, and mortality predictors in a tertiary teaching hospital in Lebanon","volume":"12","author":"Itani","year":"2023","journal-title":"Antimicrob Resist & Infect Control"},{"key":"10.1016\/j.jiph.2026.103264_bib23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3947\/ic.2013.45.3.325","article-title":"Risk factors for mortality in patients with Acinetobacter baumannii bacteremia","volume":"45","author":"Park","year":"2013","journal-title":"Infect Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fcimb.2017.00156","article-title":"Risk factors, clinical presentation, and outcome of Acinetobacter baumannii bacteremia","volume":"7","author":"Ballouz","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/cid\/cis385","article-title":"Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii Bacteremia: relation to severity of infection","volume":"55","author":"Lee","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12941-021-00442-x","article-title":"Investigation into antibacterial and wound healing properties of platelets lysate against Acinetobacter baumannii and Klebsiella pneumoniae burn wound infections","volume":"20","author":"Shariati","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jiph.2026.103264_bib27","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nrmicro1789","article-title":"An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii","volume":"5","author":"Dijkshoorn","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12879-021-07024-4","article-title":"Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019","volume":"22","author":"Pogue","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib29","first-page":"417","article-title":"Economic burden of healthcare-associated infections: an American perspective","volume":"9","author":"Stone","year":"2009","journal-title":"Expert Rev Pharm Outcomes Res"},{"key":"10.1016\/j.jiph.2026.103264_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011520","article-title":"Portrait of a killer: uncovering resistance mechanisms and global spread of Acinetobacter baumannii","volume":"19","author":"Cain","year":"2023","journal-title":"PLOS Pathog"},{"key":"10.1016\/j.jiph.2026.103264_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12941-020-00411-w","article-title":"First detection of a plasmid-encoded New-Delhi metallo-beta-lactamase-1 (NDM-1) producing Acinetobacter baumannii using whole genome sequencing, isolated in a clinical setting in Benin","volume":"20","author":"Yehouenou","year":"2021","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jiph.2026.103264_bib32","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jac\/dkl509","article-title":"Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii","volume":"59","author":"Vila","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/1471-2180-8-216","article-title":"Acinetobacter baumannii invades epithelial cells and outer membrane protein A mediates interactions with epithelial cells","volume":"8","author":"Choi","year":"2008","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2180-13-245","article-title":"Carbapenem-resistant Acinetobacter baumannii from Brazil: role of car O alleles expression and bla OXA-23 gene","volume":"13","author":"Fonseca","year":"2013","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib35","doi-asserted-by":"crossref","first-page":"6238","DOI":"10.1038\/ncomms7238","article-title":"Metabolic cross-feeding via intercellular nanotubes among bacteria","volume":"6","author":"Pande","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiph.2026.103264_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00334-19","article-title":"Intercellular transfer of chromosomal antimicrobial resistance genes between Acinetobacter baumannii strains mediated by prophages","volume":"63","author":"Wachino","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib37","article-title":"Passive immunization with chitosan-loaded biofilm-associated protein against Acinetobacter baumannii murine infection model","volume":"20","author":"Eslam","year":"2020","journal-title":"Gene Rep"},{"key":"10.1016\/j.jiph.2026.103264_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-019-4272-0","article-title":"Virulence characteristics of multidrug resistant biofilm forming Acinetobacter baumannii isolated from intensive care unit patients","volume":"19","author":"Zeighami","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib39","first-page":"14","article-title":"The VBNC state: a fundamental survival strategy of Acinetobacter baumannii","author":"K\u00f6nig","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.jiph.2026.103264_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/21505594.2025.2490209","article-title":"The response to desiccation in Acinetobacter baumannii","volume":"16","author":"Lucidi","year":"2025","journal-title":"Virulence"},{"key":"10.1016\/j.jiph.2026.103264_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01381-24","article-title":"Deciphering meropenem persistence in Acinetobacter baumannii facilitates discovery of anti-persister activity of thymol","volume":"69","author":"Hussain","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126582","article-title":"Evasion of antimicrobial activity in Acinetobacter baumannii by target site modifications: an effective resistance mechanism","volume":"23","author":"Mart\u00ednez-Trejo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jiph.2026.103264_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s43856-024-00516-9","article-title":"Overcoming challenges in the economic evaluation of interventions to optimise antibiotic use","volume":"4","author":"Roope","year":"2024","journal-title":"Commun Med"},{"key":"10.1016\/j.jiph.2026.103264_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fmicb.2013.00047","article-title":"The multifaceted roles of antibiotics and antibiotic resistance in nature","volume":"4","author":"Sengupta","year":"2013","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib45","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1093\/cid\/ciu392","article-title":"The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett","volume":"59","author":"Spellberg","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/003335491412900402","article-title":"Antibiotic resistance: a public health crisis","volume":"129","author":"Lushniak","year":"2014","journal-title":"Public Health Rep"},{"key":"10.1016\/j.jiph.2026.103264_bib47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/emph\/eou024","article-title":"Antibiotic resistance management","volume":"2014","author":"Read","year":"2014","journal-title":"Evol Med Public Health"},{"key":"10.1016\/j.jiph.2026.103264_bib48","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/s41598-021-81356-8","article-title":"Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection","volume":"11","author":"Jahangiri","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiph.2026.103264_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.imlet.2023.08.004","article-title":"Enhanced immunoprotection against Acinetobacter baumannii infection: Synergistic effects of Bap and BauA in a murine model","volume":"262","author":"Mansouri","year":"2023","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jiph.2026.103264_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2023.106262","article-title":"A two-protein cocktail elicits a protective immune response against Acinetobacter baumannii in a murine infection model","volume":"182","author":"Mirali","year":"2023","journal-title":"Microb Pathog"},{"key":"10.1016\/j.jiph.2026.103264_bib51","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s10989-020-10056-0","article-title":"Outer membrane protein, Oma87 prevents Acinetobacter baumannii infection","volume":"26","author":"Rasooli","year":"2020","journal-title":"Int J Pept Res Ther"},{"key":"10.1016\/j.jiph.2026.103264_bib52","article-title":"Anti-Omp34 antibodies protect against Acinetobacter baumannii in a murine sepsis model","volume":"161","author":"Erami","year":"2021","journal-title":"Microb Pathog"},{"key":"10.1016\/j.jiph.2026.103264_bib53","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s43141-022-00325-4","article-title":"Immunity induced by valine-glycine repeat protein G imparts histoprotection of vital body organs against Acinetobacter baumannii","volume":"20","author":"Alipouri","year":"2022","journal-title":"J Genet Eng Biotechnol"},{"key":"10.1016\/j.jiph.2026.103264_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108731","article-title":"BauA and Omp34 surface loops trigger protective antibodies against Acinetobacter baumannii in a murine sepsis model","volume":"108","author":"Akbari","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jiph.2026.103264_bib55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molimm.2022.06.010","article-title":"Immunoprotective characterization of egg yolk immunoglobulin raised to loop 3 of outer membrane protein 34 (Omp34) in a murine model against Acinetobacter baumannii","volume":"149","author":"Moghaddam","year":"2022","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jiph.2026.103264_bib56","doi-asserted-by":"crossref","first-page":"12576","DOI":"10.1038\/s41598-022-16894-w","article-title":"Specific egg yolk antibody raised to biofilm associated protein (Bap) is protective against murine pneumonia caused by Acinetobacter baumannii","volume":"12","author":"Ranjbar","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiph.2026.103264_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jiph.2026.103264_bib58","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.drudis.2022.05.026","article-title":"Drug repurposing: an effective strategy to accelerate contemporary drug discovery","volume":"27","author":"Zhan","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jiph.2026.103264_bib59","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8885338","article-title":"Repurposing of drugs for antibacterial activities on selected ESKAPE bacteria staphylococcus aureus and Pseudomonas aeruginosa","volume":"2020","author":"Kamurai","year":"2020","journal-title":"Int J Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib60","doi-asserted-by":"crossref","DOI":"10.1186\/s12866-023-02904-y","article-title":"Increased ompW and ompA expression and higher virulence of Acinetobacter baumannii persister cells","volume":"23","author":"Schmitt","year":"2023","journal-title":"BMC Microbiol"},{"issue":"8","key":"10.1016\/j.jiph.2026.103264_bib61","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1099\/jmm.0.000542","article-title":"Combination of polymyxin B and meropenem eradicates persister cells from Acinetobacter baumannii strains in exponential growth","volume":"66","author":"Gallo","year":"2017","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib62","article-title":"Efficacy of tamoxifen metabolites in combination with colistin and tigecycline in experimental murine models of Escherichia coli and Acinetobacter baumannii","volume":"13","author":"Herrera-Espejo","year":"2024","journal-title":"Antibiot (Basel)"},{"key":"10.1016\/j.jiph.2026.103264_bib63","first-page":"14","article-title":"Potential tamoxifen repurposing to combat infections by multidrug-resistant gram-negative bacilli","author":"Mir\u00f3-Canturri","year":"2021","journal-title":"Pharm (Basel)"},{"key":"10.1016\/j.jiph.2026.103264_bib64","first-page":"10","article-title":"Repurposing of the tamoxifen metabolites to combat infections by multidrug-resistant gram-negative bacilli","author":"Mir\u00f3-Canturri","year":"2021","journal-title":"Antibiot (Basel)"},{"key":"10.1016\/j.jiph.2026.103264_bib65","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijantimicag.2016.08.022","article-title":"Repurposing the anticancer drug mitomycin C for the treatment of persistent Acinetobacter baumannii infections","volume":"49","author":"Cruz-Mu\u00f1iz","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2026.103264_bib66","article-title":"Benzothiazole-phthalimide hybrids as anti-breast cancer and antimicrobial agents","volume":"12","author":"Barbarossa","year":"2023","journal-title":"Antibiot (Basel)"},{"key":"10.1016\/j.jiph.2026.103264_bib67","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3389\/fmicb.2018.00721","article-title":"Novel polymyxin combination with antineoplastic mitotane improved the bacterial killing against polymyxin-resistant multidrug-resistant gram-negative pathogens","volume":"9","author":"Tran","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib68","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fcimb.2018.00348","article-title":"Synergistic activity of niclosamide in combination with colistin against colistin-susceptible and colistin-resistant Acinetobacter baumannii and Klebsiella pneumoniae","volume":"8","author":"Ayerbe-Algaba","year":"2018","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib69","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/jac\/dkaa103","article-title":"Repositioning rafoxanide to treat Gram-negative bacilli infections","volume":"75","author":"Mir\u00f3-Canturri","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib70","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ijantimicag.2019.07.006","article-title":"The anthelmintic oxyclozanide restores the activity of colistin against colistin-resistant Gram-negative bacilli","volume":"54","author":"Ayerbe-Algaba","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2026.103264_bib71","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00284-023-03242-y","article-title":"Repositioning of benzodiazepine drugs and synergistic effect with ciprofloxacin against ESKAPE pathogens","volume":"80","author":"Da Rosa","year":"2023","journal-title":"Curr Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib72","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11274-021-03016-3","article-title":"Repositioning of antidepressant drugs and synergistic effect with ciprofloxacin against multidrug-resistant bacteria","volume":"37","author":"Foletto","year":"2021","journal-title":"World J Microbiol Biotechnol"},{"key":"10.1016\/j.jiph.2026.103264_bib73","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1111\/jam.15109","article-title":"Antibacterial properties of phenothiazine derivatives against multidrug-resistant Acinetobacter baumannii strains","volume":"131","author":"Aguilar-Vega","year":"2021","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib74","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1021\/acsinfecdis.8b00150","article-title":"Siderophore conjugates of daptomycin are potent inhibitors of carbapenem resistant strains of Acinetobacter baumannii","volume":"4","author":"Ghosh","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib75","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/mdr.2019.0075","article-title":"Dissemination of International Clone II Acinetobacter baumannii strains coproducing OXA-23 carbapenemase and 16S rRNA methylase ArmA in Athens, Greece","volume":"26","author":"Nafplioti","year":"2020","journal-title":"Micro Drug Resist"},{"key":"10.1016\/j.jiph.2026.103264_bib76","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02585-17","article-title":"Efficacy of apramycin against multidrug-resistant Acinetobacter baumannii in the murine neutropenic thigh model","volume":"62","author":"Kang","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib77","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.diagmicrobio.2017.03.006","article-title":"Invitro apramycin activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"88","author":"Kang","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib78","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41429-019-0268-7","article-title":"Antibiotic repurposing: bis-catechol- and mixed ligand (bis-catechol-mono-hydroxamate)-teicoplanin conjugates are active against multidrug resistant Acinetobacter baumannii","volume":"73","author":"Ghosh","year":"2020","journal-title":"J Antibiot"},{"key":"10.1016\/j.jiph.2026.103264_bib79","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02295-23","article-title":"Antiparasitic nitazoxanide potentiates colistin against colistin-resistant Acinetobacter baumannii and Escherichia coli in vitro and in vivo","volume":"12","author":"Xu","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jiph.2026.103264_bib80","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/jac\/dkac123","article-title":"vitro activity of nitroxoline against carbapenem-resistant Acinetobacter baumannii isolated from the urinary tract","volume":"77","author":"Fuchs","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012705","article-title":"Diclofenac sensitizes multi-drug resistant Acinetobacter baumannii to colistin","volume":"20","author":"Bisaro","year":"2024","journal-title":"PLOS Pathog"},{"key":"10.1016\/j.jiph.2026.103264_bib82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2217\/fmb-2022-0085","article-title":"Antimicrobial and antibiofilm activities of desloratadine against multidrug-resistant Acinetobacter baumannii","volume":"18","author":"Eduvirgem","year":"2023","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106582","article-title":"Repurposing non-antibiotic drugs auranofin and pentamidine in combination to combat multidrug-resistant gram-negative bacteria","volume":"59","author":"Yu","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2026.103264_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14040786","article-title":"Mechanisms underlying synergistic killing of polymyxin b in combination with cannabidiol against Acinetobacter baumannii: a metabolomic study","volume":"14","author":"Hussein","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jiph.2026.103264_bib85","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1476-0711-11-13","article-title":"Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin","volume":"11","author":"Masadeh","year":"2012","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jiph.2026.103264_bib86","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/6360187","article-title":"Targeting shikimate kinase pathway of Acinetobacter baumannii: a structure-based computational approach to identify antibacterial compounds","volume":"2023","author":"Shil","year":"2023","journal-title":"J Trop Med"},{"key":"10.1016\/j.jiph.2026.103264_bib87","article-title":"Antibacterial activity of tamoxifen derivatives against methicillin-resistant Staphylococcus aureus","volume":"16","author":"Panadero","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiph.2026.103264_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms9369","article-title":"Tamoxifen augments the innate immune function of neutrophils through modulation of intracellular ceramide","volume":"6","author":"Corriden","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiph.2026.103264_bib89","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1021\/cb500828m","article-title":"Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and NAPE phospholipase D enzymes","volume":"10","author":"Scott","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jiph.2026.103264_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2019.01556","article-title":"Repurposed antimicrobial combination therapy: tobramycin-ciprofloxacin hybrid augments activity of the anticancer drug mitomycin C against multidrug-resistant gram-negative bacteria","volume":"10","author":"Domalaon","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib91","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.amjmed.2004.03.040","article-title":"Adverse effects of thalidomide administration in patients with neoplastic diseases","volume":"117","author":"Dimopoulos","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jiph.2026.103264_bib92","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1139\/cjm-2020-0546","article-title":"Repurposing of escitalopram oxalate and clonazepam in combination with ciprofloxacin and sulfamethoxazole-trimethoprim for treatment of multidrug-resistant microorganisms and evaluation of the cleavage capacity of plasmid DNA","volume":"67","author":"Rosa","year":"2021","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib93","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.3390\/molecules25173959","article-title":"Potential of 2-Chloro-N-(4-fluoro-3-nitrophenyl)acetamide Against Klebsiella pneumoniae and In Vitro Toxicity Analysis","volume":"25","author":"Cordeiro","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jiph.2026.103264_bib94","first-page":"38930","article-title":"Phenothiazines and their evolving roles in clinical practice: a narrative review","volume":"10","author":"Edinoff","year":"2022","journal-title":"Health Psychol Res"},{"key":"10.1016\/j.jiph.2026.103264_bib95","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01023-23","article-title":"Type IV pilus-mediated inhibition of Acinetobacter baumannii biofilm formation by phenothiazine compounds","volume":"11","author":"Vo","year":"2023","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jiph.2026.103264_bib96","first-page":"Cd001718","article-title":"Depot fluspirilene for schizophrenia","volume":"2007","author":"Abhijnhan","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jiph.2026.103264_bib97","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/EC.00314-12","article-title":"A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis","volume":"12","author":"Butts","year":"2013","journal-title":"Eukaryot Cell"},{"key":"10.1016\/j.jiph.2026.103264_bib98","article-title":"Apralogs: apramycin 5-O-glycosides and ethers with improved antibacterial activity and ribosomal selectivity and reduced susceptibility to the aminoacyltranserferase (3)-IV resistance determinant","author":"Quirke","year":"2019","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jiph.2026.103264_bib99","first-page":"95","article-title":"Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens","volume":"3","author":"Beiras-Fernandez","year":"2010","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiph.2026.103264_bib100","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00003495-199040030-00007","article-title":"Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential","volume":"40","author":"Campoli-Richards","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.jiph.2026.103264_bib101","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41429-019-0268-7","article-title":"Antibiotic repurposing: bis-catechol- and mixed ligand (bis-catechol-mono-hydroxamate)-teicoplanin conjugates are active against multidrug resistant Acinetobacter baumannii","volume":"73","author":"Ghosh","year":"2020","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.jiph.2026.103264_bib102","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02574-18","article-title":"The anthelmintic drug niclosamide synergizes with colistin and reverses colistin resistance in gram-negative bacilli","volume":"63","author":"Domalaon","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib103","doi-asserted-by":"crossref","first-page":"637","DOI":"10.4269\/ajtmh.1997.56.637","article-title":"Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa","volume":"56","author":"Doumbo","year":"1997","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.jiph.2026.103264_bib104","article-title":"Uncovering nitroxoline activity spectrum, mode of action and resistance across Gram-negative bacteria","author":"Cacace","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.jiph.2026.103264_bib105","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1185\/030079908X273066","article-title":"Topical diclofenac and its role in pain and inflammation: an evidence-based review","volume":"24","author":"Zacher","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jiph.2026.103264_bib106","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/13543784.10.3.547","article-title":"Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug","volume":"10","author":"Agrawal","year":"2001","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.jiph.2026.103264_bib107","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12672-021-00439-0","article-title":"The gold complex auranofin: new perspectives for cancer therapy","volume":"12","author":"Abdalbari","year":"2021","journal-title":"Discov Oncol"},{"key":"10.1016\/j.jiph.2026.103264_bib108","article-title":"A macromolecule reversing antibiotic resistance phenotype and repurposing drugs as potent antibiotics","volume":"7","author":"Ding","year":"2020","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.jiph.2026.103264_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093067","article-title":"Cannabidiol and other non-psychoactive cannabinoids for prevention and treatment of gastrointestinal disorders: useful nutraceuticals?","volume":"21","author":"Mart\u00ednez","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jiph.2026.103264_bib110","doi-asserted-by":"crossref","DOI":"10.1128\/mmbr.00044-22","article-title":"At the crossroad of nucleotide dynamics and protein synthesis in bacteria","volume":"87","author":"Leiva","year":"2023","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.jiph.2026.103264_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313128","article-title":"Peptidome: chaos or inevitability","volume":"22","author":"Lyapina","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jiph.2026.103264_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105986","article-title":"The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury","volume":"175","author":"Bland","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jiph.2026.103264_bib113","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jobm.201100614","article-title":"Effect of HMG-CoA reductase inhibitors on antimicrobial susceptibilities for gram-negative rods","volume":"53","author":"Farmer","year":"2013","journal-title":"J Basic Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib114","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/jac\/dkac057","article-title":"Disulfiram enhances meropenem activity against NDM- and IMP-producing carbapenem-resistant Acinetobacter baumannii infections","volume":"77","author":"Dubey","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2025.1619416","article-title":"Disulfiram inhibits bacterial growth by inducing zinc-dependent reactive oxygen species","volume":"16","author":"Luo","year":"2025","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11030129","article-title":"Challenges and recent progress in oral drug delivery systems for biopharmaceuticals","volume":"11","author":"Homayun","year":"2019","journal-title":"Pharmaceutics"},{"issue":"18","key":"10.1016\/j.jiph.2026.103264_bib117","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2146\/ajhp140630","article-title":"Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings","volume":"72","author":"Corrigan","year":"2015","journal-title":"Am J Health-Syst Pharm AJHP J Am Soc Health-Syst Pharm"},{"key":"10.1016\/j.jiph.2026.103264_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetpar.2021.109525","article-title":"Route of administration affects the efficacy of moxidectin against Ostertagiinae nematodes in farmed red deer (Cervus elaphus)","volume":"298","author":"Leathwick","year":"2021","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.jiph.2026.103264_bib119","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-021-05919-w","article-title":"Systematic review: the bioavailability of orally administered antibiotics during the initial phase of a systemic infection in non-ICU patients","volume":"21","author":"Van Den Broek","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fmedt.2021.778645","article-title":"Drug delivery systems for the oral administration of antimicrobial peptides: promising tools to treat infectious diseases","volume":"3","author":"Deshayes","year":"2022","journal-title":"Front Med Technol"},{"key":"10.1016\/j.jiph.2026.103264_bib121","doi-asserted-by":"crossref","DOI":"10.3390\/polysaccharides6010021","article-title":"Chondroitin sulfate\/cyanocobalamin\u2013chitosan polyelectrolyte complexes for improved oral delivery of colistin","author":"Dubashynskaya","year":"2025","journal-title":"Polysaccharides"},{"key":"10.1016\/j.jiph.2026.103264_bib122","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209425","article-title":"Intestinal carriage of antibiotic resistant Acinetobacter baumannii among newborns hospitalized in Moroccan neonatal intensive care unit","volume":"14","author":"Arhoune","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jiph.2026.103264_bib123","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s10096-010-1030-z","article-title":"Gut colonization by multidrug-resistant and carbapenem-resistant Acinetobacter baumannii in neonates","volume":"29","author":"Roy","year":"2010","journal-title":"Eur J Clin Microbiol & Infect Dis"},{"issue":"9","key":"10.1016\/j.jiph.2026.103264_bib124","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ajic.2010.03.005","article-title":"Patients with Acinetobacter baumannii bloodstream infections are colonized in the gastrointestinal tract with identical strains","volume":"38","author":"Thom","year":"2010","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.jiph.2026.103264_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2021.698135","article-title":"Pharmacokinetics of colistin in the gastrointestinal tract of poultry following dosing via drinking water and its bactericidal impact on enteric Escherichia coli","volume":"8","author":"Mead","year":"2021","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.jiph.2026.103264_bib126","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202301182R","article-title":"Disruption of the primocolonizing microbiota alters epithelial homeostasis and imprints stem cells in the colon of neonatal piglets","volume":"37","author":"Beaumont","year":"2023","journal-title":"Faseb J"},{"issue":"669","key":"10.1016\/j.jiph.2026.103264_bib127","article-title":"Impact of issuing longer- versus shorter-duration prescriptions: a systematic review","volume":"68","author":"King","year":"2018","journal-title":"Br J Gen Pr J R Coll Gen Pr"},{"key":"10.1016\/j.jiph.2026.103264_bib128","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cpdd.907","article-title":"Pharmacokinetic and pharmacodynamic target attainment in adult and pediatric patients following administration of ceftaroline fosamil as a 5-minute infusion","volume":"10","author":"Riccobene","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jiph.2026.103264_bib129","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/0962280216631763","article-title":"Phase I\/II dose-finding design for molecularly targeted agent: plateau determination using adaptive randomization","volume":"27","author":"Riviere","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jiph.2026.103264_bib130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2019.08.002","article-title":"Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies","volume":"120","author":"Corbaux","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jiph.2026.103264_bib131","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cct.2018.06.012","article-title":"Efficacy\/toxicity dose-finding using hierarchical modeling for multiple populations","volume":"71","author":"Cunanan","year":"2018","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jiph.2026.103264_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106368","article-title":"Antibiotic pharmacokinetic\/pharmacodynamic modeling: MIC, Pharmacodynamic indices, and beyond","author":"Rao","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2026.103264_bib133","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00280-025-04821-5","article-title":"Pharmacokinetics of UGN\u2011102, an investigational mitomycin\u2011containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer","volume":"95","author":"Prasad","year":"2025","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jiph.2026.103264_bib134","first-page":"805","article-title":"Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination","volume":"67","author":"Van Hazel","year":"1983","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.jiph.2026.103264_bib135","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00108-23","article-title":"Eradication of staphylococcus epidermidis within biofilms: comparison of systemic versus supratherapeutic concentrations of antibiotics","volume":"67","author":"Daffinee","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.770518","article-title":"Limitations of antibiotic MIC-based PK-PD metrics: looking back to move forward","volume":"12","author":"Landersdorfer","year":"2021","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.jiph.2026.103264_bib137","first-page":"1476","article-title":"Cost-effectiveness analysis of branded drugs with market demand and insurance","volume":"24","author":"Pauly","year":"2021","journal-title":"Value Health J Int Soc Pharm Outcomes Res"},{"key":"10.1016\/j.jiph.2026.103264_bib138","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S2055-6640(20)30018-2","article-title":"Minimum costs to manufacture new treatments for COVID-19","volume":"6","author":"Hill","year":"2020","journal-title":"J Virus Erad"},{"key":"10.1016\/j.jiph.2026.103264_bib139","doi-asserted-by":"crossref","DOI":"10.1002\/bjs.1800750905","article-title":"Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial","volume":"75","author":"Fentiman","year":"1988","journal-title":"Br J Surg"},{"issue":"10","key":"10.1016\/j.jiph.2026.103264_bib140","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1023\/A:1008269025294","article-title":"Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction","volume":"9","author":"Floren","year":"1998","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.jiph.2026.103264_bib141","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-006-9483-6","volume":"106","author":"Locker","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jiph.2026.103264_bib142","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071373","article-title":"Long-term oral tamoxifen administration decreases brain-derived neurotrophic factor in the hippocampus of female long-evans rats","volume":"16","author":"Been","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jiph.2026.103264_bib143","doi-asserted-by":"crossref","DOI":"10.1111\/andr.12197","article-title":"Tamoxifen in men: a review of adverse events","volume":"4","author":"Wibowo","year":"2016","journal-title":"Andrology"},{"issue":"4","key":"10.1016\/j.jiph.2026.103264_bib144","first-page":"619","article-title":"Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen","volume":"2","author":"Couldwell","year":"1996","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"19","key":"10.1016\/j.jiph.2026.103264_bib145","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/jnci\/90.19.1461","article-title":"Biologic activity of tamoxifen at low doses in healthy women","volume":"90","author":"Decensi","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jiph.2026.103264_bib146","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia","volume":"37","author":"Decensi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4_","key":"10.1016\/j.jiph.2026.103264_bib147","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/jco.2011.29.4_suppl.547","article-title":"Modeling 5-FU AUC-dose relationship to develop a PK dosing algorithm","volume":"29","author":"Haregewoin","year":"2011","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.jiph.2026.103264_bib148","first-page":"998","article-title":"Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons","volume":"70","author":"Anderson","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.jiph.2026.103264_bib149","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.3542","article-title":"A prospective, multi-center study of individualized, pharmacokinetically (PK)-guided dosing of 5-fluorouracil (5-FU) in metastatic colorectal cancer (mCRC) patients treated with weekly or biweekly 5-FU\/oxaliplatin containing regimens","volume":"33","author":"Kunzmann","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jiph.2026.103264_bib150","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1515\/cclm-2018-1177","article-title":"Therapeutic drug monitoring (TDM) of 5-fluorouracil (5-FU): new preanalytic aspects","volume":"57","author":"Mindt","year":"2019","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"10.1016\/j.jiph.2026.103264_bib151","article-title":"Administration mode matters for 5-fluorouracil therapy: physiologically based pharmacokinetic evidence for avoidance of myelotoxicity by continuous infusion but not intravenous bolus","author":"Chao","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiph.2026.103264_bib152","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00255484","article-title":"Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma","volume":"8","author":"Konits","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"10.1016\/j.jiph.2026.103264_bib153","first-page":"5959","article-title":"Phase I trial of parenteral 6-thioguanine given on 5 consecutive days","volume":"46","author":"Kovach","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.jiph.2026.103264_bib154","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212157","article-title":"Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: a systematic review","volume":"14","author":"Toksvang","year":"2019","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.jiph.2026.103264_bib155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.crohns.2011.07.009","article-title":"Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment","volume":"6","author":"Van Asseldonk","year":"2012","journal-title":"J Crohn's & Colitis"},{"key":"10.1016\/j.jiph.2026.103264_bib156","first-page":"35","article-title":"Clinical pharmacology of oral thioguanine in acute myelogenous leukemia","volume":"6","author":"Brox","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.jiph.2026.103264_bib157","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0161-6420(99)00096-2","article-title":"A randomized trial of low-dose, topical mitomycin-C in the treatment of severe vernal keratoconjunctivitis","volume":"107","author":"Akpek","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jiph.2026.103264_bib158","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/cam4.491","article-title":"Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients","volume":"4","author":"Golan","year":"2015","journal-title":"Cancer Med"},{"issue":"1-2","key":"10.1016\/j.jiph.2026.103264_bib159","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijpharm.2004.04.017","article-title":"Evaluation of antitumor and toxic side effects of mitomycin C-estradiol conjugates","volume":"279","author":"Ishiki","year":"2004","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.jiph.2026.103264_bib160","first-page":"44","article-title":"Comparison of 30 mg and 40 mg of mitomycin C intravesical instillation in Korean superficial bladder cancer patients: prospective, randomized study","volume":"37","author":"Jeong","year":"2005","journal-title":"Cancer research treatment official journal Korean Cancer Association"},{"issue":"5","key":"10.1016\/j.jiph.2026.103264_bib161","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0360-3016(02)04405-X","article-title":"Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial","volume":"55","author":"Lorvidhaya","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jiph.2026.103264_bib162","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.otohns.2005.10.057","article-title":"Mitomycin-c application in airway stenosis surgery: analysis of safety and costs","volume":"134","author":"Ubell","year":"2005","journal-title":"OtolaryngolHead Neck Surg"},{"key":"10.1016\/j.jiph.2026.103264_bib163","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(19850101)55:1<47::AID-CNCR2820550108>3.0.CO;2-#","article-title":"Renal complications of mitomycin C therapy with special reference to the total dose","volume":"55","author":"Valavaara","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.jiph.2026.103264_bib164","first-page":"e413","article-title":"MP29-03 cost implications of perioperative intravesical chemotherapy for bladder tumor resection: gemcitabine versus mitomycin-C","volume":"201","author":"Bens","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.jiph.2026.103264_bib165","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2141.2007.06817.x","article-title":"Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study","volume":"139","author":"Feyler","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jiph.2026.103264_bib166","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s00277-005-1007-7","article-title":"Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival","volume":"84","author":"Sch\u00fctt","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jiph.2026.103264_bib167","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2141.2001.02918.x","article-title":"Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia","volume":"114","author":"Barosi","year":"2001","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jiph.2026.103264_bib168","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaad.2015.01.002","article-title":"Review of thalidomide use in the pediatric population","volume":"72","author":"Yang","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"15_","key":"10.1016\/j.jiph.2026.103264_bib169","article-title":"Cost differences among treatment options for patients with refractory myeloma previously treated with high-dose chemotherapy and autologous stem-cell transplantation: an analysis from the U.S. and Swiss perspectives","volume":"29","author":"Blank","year":"2011","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.jiph.2026.103264_bib170","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1567205014666170117141330","article-title":"Poor safety and tolerability hamper reaching a potentially therapeutic dose in the use of thalidomide for Alzheimer's disease: results from a double-blind, placebo-controlled trial","volume":"14","author":"Decourt","year":"2017","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"10.1016\/j.jiph.2026.103264_bib171","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1530\/EJE-11-0557","article-title":"High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up","volume":"166","author":"Maucl\u00e8re-Denost","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jiph.2026.103264_bib172","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092615","article-title":"Unwanted hormonal and metabolic effects of postoperative adjuvant mitotane treatment for adrenocortical cancer","volume":"12","author":"Basile","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.jiph.2026.103264_bib173","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-12-0358","article-title":"Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center","volume":"167","author":"Baudry","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.jiph.2026.103264_bib174","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/en.2009-1404","article-title":"Therapeutic concentrations of mitotane (o,p\u2032-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model","volume":"151","author":"Zatelli","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.jiph.2026.103264_bib175","unstructured":"DRUGS.COM. 2025c. Lysodren Price Guide [Online]. Available: \u3008https:\/\/www.drugs.com\/price-guide\/lysodren\u3009 [Accessed January 22, 2025]."},{"key":"10.1016\/j.jiph.2026.103264_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxlet.2021.04.018","article-title":"The ameliorative effect of niclosamide on bile duct ligation induced liver fibrosis via suppression of NOTCH and Wnt pathways","author":"Esmail","year":"2021","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.jiph.2026.103264_bib177","first-page":"14","article-title":"Systematic review of the effectiveness of selected drugs for preventive chemotherapy for Taenia solium taeniasis","author":"Haby","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120701","article-title":"Niclosamide inhalation powder made by thin-film freezing: multi-dose tolerability and exposure in rats and pharmacokinetics in hamsters","volume":"603","author":"Jara","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jiph.2026.103264_bib179","first-page":"4","article-title":"A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: a broad spectrum antiviral candidate for treatment of COVID-19","author":"Backer","year":"2021","journal-title":"Lancet Reg Health - Eur"},{"key":"10.1016\/j.jiph.2026.103264_bib180","article-title":"A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer","volume":"13","author":"Schweizer","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jiph.2026.103264_bib181","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44942","article-title":"Efficacy of niclosamide vs placebo in SARS-CoV-2 respiratory viral clearance, viral shedding, and duration of symptoms among patients with mild to moderate COVID-19: a phase 2 randomized clinical trial","volume":"5","author":"Cairns","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jiph.2026.103264_bib182","doi-asserted-by":"crossref","first-page":"154","DOI":"10.21608\/kvmj.2007.115888","article-title":"Some hematological and biochemical alterations consequent to concurrent administration of ivermectin and rafoxanide in rams","volume":"5","author":"El-ghoneimy","year":"2007","journal-title":"Kafrelsheikh Vet Med J"},{"key":"10.1016\/j.jiph.2026.103264_bib183","first-page":"119","article-title":"Adverse effects of ivermectin in comparison with rafoxanide on male rats","volume":"47","author":"Elsawy","year":"2015","journal-title":"Alex J Vet Sci"},{"key":"10.1016\/j.jiph.2026.103264_bib184","unstructured":"INDIAMART. 2025. Rafoxanide Powder [Online]. Available: \u3008https:\/\/dir.indiamart.com\/impcat\/rafoxanide-powder.html\u3009 [Accessed January 22, 2025]."},{"issue":"2","key":"10.1016\/j.jiph.2026.103264_bib185","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2885.1987.tb00089.x","article-title":"The pharmacodynamics of the flukicidal salicylanilides, rafoxanide, closantel and oxyclosanide","volume":"10","author":"Mohammed-Ali","year":"1987","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1016\/j.jiph.2026.103264_bib186","doi-asserted-by":"crossref","DOI":"10.1002\/jat.2550130208","article-title":"Oral toxicity in weanling and adult rats and in vitro genotoxicity of the veterinary anthelmintic rafoxanide","volume":"13","author":"Poul","year":"1993","journal-title":"J Appl Toxicol"},{"issue":"1-2","key":"10.1016\/j.jiph.2026.103264_bib187","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0304-4017(86)90040-3","article-title":"The use of injectable rafoxanide against natural ovine nasal myiasis","volume":"19","author":"Sanyal","year":"1986","journal-title":"Vet Parasitol"},{"issue":"1","key":"10.1016\/j.jiph.2026.103264_bib188","first-page":"29","article-title":"The safety of injectable rafoxanide in cattle","volume":"53","author":"Schr\u00f6der","year":"1982","journal-title":"J South Afr Vet Assoc"},{"key":"10.1016\/j.jiph.2026.103264_bib189","first-page":"289","article-title":"Effect of chronic rafoxanide administration on behavioural and physiological parameters in the rat","volume":"29","author":"Stephen","year":"1997","journal-title":"Indian J Pharmacol"},{"issue":"2","key":"10.1016\/j.jiph.2026.103264_bib190","first-page":"123","article-title":"A safety trial with rafoxanide in sheep","volume":"52","author":"Swan","year":"1981","journal-title":"J South Afr Vet Assoc"},{"issue":"3","key":"10.1016\/j.jiph.2026.103264_bib191","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0020-7519(77)90050-9","article-title":"The in vivo effects of rafoxanide on the energy metabolism of Fasciola hepatica","volume":"7","author":"Cornish","year":"1977","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.jiph.2026.103264_bib192","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1017\/S0031182000045285","article-title":"The effect of oxyclozanide on Hymenolepis microstoma and H. diminuta","volume":"66","author":"Hopkins","year":"1973","journal-title":"Parasitology"},{"key":"10.1016\/j.jiph.2026.103264_bib193","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2019.00294","article-title":"Acute and subacute toxicity assessment of oxyclozanide in wistar rats","volume":"6","author":"Wang","year":"2019","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.jiph.2026.103264_bib194","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.yrtph.2019.01.012","article-title":"Target animal safety testing of an oral salicylanilide suspension, oxyclozanide, for the treatment of fascioliasis in bovine in China","volume":"103","author":"Dong","year":"2019","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.jiph.2026.103264_bib195","first-page":"82","article-title":"Clonazepam in the treatment of epilepsy","volume":"53","author":"Lund","year":"1973","journal-title":"Acta Neurol Scand Suppl"},{"issue":"9","key":"10.1016\/j.jiph.2026.103264_bib196","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4088\/JCP.v60n0907","article-title":"Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages","volume":"60","author":"Moroz","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jiph.2026.103264_bib197","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-0404.1973.tb02278.x","article-title":"A controlled trial on ro 5-4023 (clonazepam) in the treatment of psychomotor epilepsy","volume":"49","author":"Birket-Smith","year":"1973","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jiph.2026.103264_bib198","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archneur.1976.00500050012003","article-title":"Clonazepam. a review of a new anticonvulsant drug","volume":"33","author":"Browne","year":"1976","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jiph.2026.103264_bib199","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.25.3.255","article-title":"Serum clonazepam concentrations in children with absence seizures","volume":"25","author":"Dreifuss","year":"1975","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jiph.2026.103264_bib200","first-page":"435","article-title":"Use of low-dose fluoxetine in major depression and panic disorder","volume":"54","author":"Louie","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jiph.2026.103264_bib201","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.6199","article-title":"Fluoxetine-induced alteration of murine gut microbial community structure: evidence for a microbial endocrinology-based mechanism of action responsible for fluoxetine-induced side effects","volume":"7","author":"Lyte","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.jiph.2026.103264_bib202","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4103\/ijp.ijp_854_22","article-title":"Cost-minimization analysis of escitalopram, fluoxetine, and amitriptyline in the treatment of depression","volume":"55","author":"Raghav","year":"2023","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.jiph.2026.103264_bib203","first-page":"10","article-title":"Fluoxetine for adults who are overweight or obese","author":"Serralde-Z\u00fa\u00f1iga","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jiph.2026.103264_bib204","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/14740338.3.5.495","article-title":"Safety and side effect profile of fluoxetine","volume":"3","author":"Wernicke","year":"2004","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jiph.2026.103264_bib205","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1017\/S0033291715000240","article-title":"Acute fluoxetine modulates emotional processing in young adult volunteers","volume":"45","author":"Capit\u00e3o","year":"2015","journal-title":"Psychol Med"},{"key":"10.1016\/j.jiph.2026.103264_bib206","first-page":"419","article-title":"Fluoxetine in post-traumatic stress disorder","volume":"4","author":"Davidson","year":"1991","journal-title":"J Trauma Stress"},{"key":"10.1016\/j.jiph.2026.103264_bib207","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/bja\/37.5.332","article-title":"Studies of drugs given before Anaesthesia. VI. The phenothiazine derivatives","volume":"37","author":"Dundee","year":"1965","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.jiph.2026.103264_bib208","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jama.1963.03710110033006","article-title":"Phenothiazines in prevention of psychiatric hospitalization. II. Duration of treatment exposure","volume":"186","author":"Engelhardt","year":"1963","journal-title":"JAMA"},{"key":"10.1016\/j.jiph.2026.103264_bib209","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00003495-198300251-00005","article-title":"The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis","volume":"25","author":"Wampler","year":"1983","journal-title":"Drugs"},{"key":"10.1016\/j.jiph.2026.103264_bib210","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0022-3565(25)08193-5","article-title":"Studies on phenothiazine viii. antiseptic value of phenothiazine in urinary tract infections","volume":"65","author":"Deeds","year":"1939","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jiph.2026.103264_bib211","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/BF02848774","article-title":"Outcomes analysis of daptomycin use in a community hospital","volume":"24","author":"Fossaceca","year":"2007","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.jiph.2026.103264_bib212","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/jac\/dkt294","article-title":"A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis","volume":"68","author":"Kullar","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jiph.2026.103264_bib213","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijantimicag.2012.12.008","article-title":"Safety of daptomycin in patients completing more than 14 days of therapy: results from the Cubicin\u00ae Outcomes Registry and experience","volume":"41","author":"Rege","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2026.103264_bib214","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s12325-015-0267-4","article-title":"Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the european cubicin\u00ae outcomes registry and experience","volume":"32","author":"Seaton","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.jiph.2026.103264_bib215","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae217","article-title":"Counting the cost of daptomycin versus vancomycin in hospitalized patients: a cost minimization analysis","volume":"11","author":"Wagner","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib216","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1128\/AAC.01563-13","article-title":"High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis","volume":"57","author":"Carugati","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib217","doi-asserted-by":"crossref","DOI":"10.1186\/s13567-015-0291-z","article-title":"Apramycin treatment affects selection and spread of a multidrug-resistant Escherichia coli strain able to colonize the human gut in the intestinal microbiota of pigs","volume":"47","author":"Herrero-Fresno","year":"2016","journal-title":"Vet Res"},{"key":"10.1016\/j.jiph.2026.103264_bib218","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/BF02278511","article-title":"An evaluation of apramycin as an in-feed medication for the treatment of post-weaning colibacillosis in pigs","volume":"4","author":"Andreotis","year":"2005","journal-title":"Vet Res Commun"},{"key":"10.1016\/j.jiph.2026.103264_bib219","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/cpt.2104","article-title":"Model-informed drug development for antimicrobials: translational PK and PK\/PD modeling to predict an efficacious human dose for apramycin","volume":"109","author":"Sou","year":"2021","journal-title":"Clin Pharmacol & Ther"},{"key":"10.1016\/j.jiph.2026.103264_bib220","article-title":"Characterization of resistance patterns and detection of apramycin resistance genes in Escherichia coli isolated from chicken feces and houseflies after apramycin administration","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Microbiol"},{"issue":"2","key":"10.1016\/j.jiph.2026.103264_bib221","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijantimicag.2018.10.003","article-title":"Teicoplanin for treating enterococcal infective endocarditis: a retrospective observational study from a referral centre in Spain","volume":"53","author":"Escol\u00e0-Verg\u00e9","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jiph.2026.103264_bib222","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jinf.2013.08.018","article-title":"Increased teicoplanin doses are associated with improved serum levels but not drug toxicity","volume":"68","author":"Matthews","year":"2014","journal-title":"J Infect"},{"issue":"A","key":"10.1016\/j.jiph.2026.103264_bib223","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/21.suppl_A.69","article-title":"Clinical efficacy and safety of teicoplanin","volume":"21","author":"Stille","year":"1988","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib224","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/IDR.S146961","article-title":"Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate\u2013severe Gram-positive infections","volume":"11","author":"Zhou","year":"2018","journal-title":"Infect Drug Resist"},{"issue":"2","key":"10.1016\/j.jiph.2026.103264_bib225","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/clinids\/15.2.285","article-title":"Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections","volume":"15","author":"Cruciani","year":"1992","journal-title":"Clin Infect Dis Publ Infect Dis Soc Am"},{"issue":"3","key":"10.1016\/j.jiph.2026.103264_bib226","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/jac\/37.3.623","article-title":"Impact of glycopeptide therapy after hospital discharge on inpatient costs: a comparison of teicoplanin and vancomycin","volume":"37","author":"Davey","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib227","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S2055-6640(20)30017-0","article-title":"Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19","volume":"6","author":"Pepperrell","year":"2020","journal-title":"J Virus Erad"},{"key":"10.1016\/j.jiph.2026.103264_bib228","first-page":"58","article-title":"Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial","author":"Rocco","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jiph.2026.103264_bib229","article-title":"Nitazoxanide in treatment of rotavirus diarrhea in children: a single center study","author":"Adnan","year":"2021","journal-title":"J Univ Med & Dent Coll"},{"key":"10.1016\/j.jiph.2026.103264_bib230","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/cpt.2463","article-title":"An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2","volume":"111","author":"Walker","year":"2022","journal-title":"Clin Pharmacol & Ther"},{"issue":"7","key":"10.1016\/j.jiph.2026.103264_bib231","article-title":"The safety record of fusidic acid in non-US markets: a focus on skin infections","volume":"52","author":"Kraus","year":"2011","journal-title":"Clin Infect Dis Publ Infect Dis Soc Am"},{"issue":"7","key":"10.1016\/j.jiph.2026.103264_bib232","article-title":"Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects","volume":"52","author":"Still","year":"2011","journal-title":"Clin Infect Dis Publ Infect Dis Soc Am"},{"issue":"7","key":"10.1016\/j.jiph.2026.103264_bib233","article-title":"Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead","volume":"52","author":"Tsuji","year":"2011","journal-title":"Clin Infect Dis Publ Infect Dis Soc Am"},{"issue":"7","key":"10.1016\/j.jiph.2026.103264_bib234","article-title":"A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections","volume":"52","author":"Craft","year":"2011","journal-title":"Clin Infect Dis Publ Infect Dis Soc Am"},{"key":"10.1016\/j.jiph.2026.103264_bib235","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/STROKEAHA.110.582601","article-title":"Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study","volume":"41","author":"Fagan","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.jiph.2026.103264_bib236","article-title":"Minocycline for acne vulgaris: efficacy and safety","volume":"8","author":"Garner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jiph.2026.103264_bib237","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2133.1996.tb06972.x","article-title":"Safety of long-term high-dose minocycline in the treatment of acne","volume":"134","author":"Goulden","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jiph.2026.103264_bib238","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.pain.2013.03.028","article-title":"The efficacy of a glial inhibitor, minocycline, for preventing persistent pain after lumbar discectomy: a randomized, double-blind, controlled study","volume":"154","author":"Martinez","year":"2013","journal-title":"PAIN\u00ae"},{"key":"10.1016\/j.jiph.2026.103264_bib239","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3390\/antibiotics10070757","article-title":"A review of systemic minocycline side effects and topical minocycline as a safer alternative for treating acne and rosacea","volume":"10","author":"Martins","year":"2021","journal-title":"Antibiotics"},{"issue":"5","key":"10.1016\/j.jiph.2026.103264_bib240","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1352\/1944-7558-115.5.433","article-title":"Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures","volume":"115","author":"Utari","year":"2010","journal-title":"Am J Intellect Dev Disabil"},{"key":"10.1016\/j.jiph.2026.103264_bib241","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0041-008X(67)90035-X","article-title":"Morphologic effects of minocycline in laboratory animals","volume":"11","author":"Benitz","year":"1967","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jiph.2026.103264_bib242","first-page":"43","article-title":"Minocycline treatment for rheumatoid arthritis: an open dose finding study","volume":"17","author":"Breedveld","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jiph.2026.103264_bib243","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1024608","article-title":"Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy","volume":"13","author":"Deshpande","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiph.2026.103264_bib244","first-page":"339","article-title":"Nitroxoline: treatment and prevention of urinary tract infections from the urologist\u2019s perspective","volume":"77","author":"Krajewski","year":"2024","journal-title":"Cent Eur J Urol"},{"issue":"1","key":"10.1016\/j.jiph.2026.103264_bib245","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/neuonc\/nou139","article-title":"Nitroxoline induces apoptosis and slows glioma growth in vivo","volume":"17","author":"Lazovic","year":"2015","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.jiph.2026.103264_bib246","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-014-0628-7","article-title":"Review of the literature and individual patients\u2019 data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections","volume":"14","author":"Naber","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib247","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/jac\/dky255","article-title":"Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline","volume":"73","author":"Wijma","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib248","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/13880209.2020.1777169","article-title":"Gallic acid mitigates diclofenac-induced liver toxicity by modulating oxidative stress and suppressing IL-1\u03b2 gene expression in male rats","volume":"58","author":"Esmaeilzadeh","year":"2020","journal-title":"Pharm Biol"},{"key":"10.1016\/j.jiph.2026.103264_bib249","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.arcmed.2020.12.005","article-title":"Gallic acid exerts nephroprotective, anti-oxidative stress, and anti-inflammatory effects against diclofenac-induced renal injury in malerats","volume":"52","author":"Moradi","year":"2021","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jiph.2026.103264_bib250","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10787-999-0030-z","article-title":"Clinical trial on the efficacy and safety of different diclofenac formulations: multiple-unit formulations compared to enteric coated tablets in patients with activated osteoarthritis","volume":"7","author":"Schmitt","year":"1999","journal-title":"InflammoPharmacology"},{"key":"10.1016\/j.jiph.2026.103264_bib251","article-title":"Single dose oral diclofenac for acute postoperative pain in adults","author":"Derry","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jiph.2026.103264_bib252","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011509","article-title":"Single dose oral diclofenac for acute postoperative pain in adults","volume":"7","author":"Derry","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.jiph.2026.103264_bib253","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jaci.2008.12.008","article-title":"High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study","volume":"123","author":"Siebenhaar","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jiph.2026.103264_bib254","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2009.11.047","article-title":"The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria","volume":"125","author":"Staevska","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jiph.2026.103264_bib255","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200241001-00003","article-title":"A pharmacokinetic profile of desloratadine in healthy adults, including elderly","volume":"41","author":"Affrime","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiph.2026.103264_bib256","unstructured":"DRUGS.COM. 2025a. Desloratadine Prices [Online]. Available: \u3008https:\/\/www.drugs.com\/price-guide\/desloratadine\u3009 [Accessed January 22, 2025]."},{"issue":"65","key":"10.1016\/j.jiph.2026.103264_bib257","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1034\/j.1398-9995.2001.00101.x","article-title":"The pharmacologic profile of desloratadine: a review","volume":"56","author":"Henz","year":"2001","journal-title":"Allergy"},{"key":"10.1016\/j.jiph.2026.103264_bib258","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/thx.47.5.349","article-title":"Auranofin in the treatment of steroid dependent asthma: a double blind study","volume":"47","author":"Nierop","year":"1992","journal-title":"Thorax"},{"key":"10.1016\/j.jiph.2026.103264_bib259","series-title":"Seminars in arthritis and rheumatism","first-page":"255","article-title":"Auranofin: a unique oral chrysotherapeutic agent","author":"Blodgett Jr","year":"1984"},{"key":"10.1016\/j.jiph.2026.103264_bib260","first-page":"61","article-title":"Phase I clinical trial results of auranofin, a novel antiparasitic agent","author":"Capparelli","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiph.2026.103264_bib261","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/npp.2015.367","article-title":"Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis","volume":"41","author":"Haney","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jiph.2026.103264_bib262","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial","volume":"176","author":"Hurd","year":"2019","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jiph.2026.103264_bib263","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24162967","article-title":"A novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb\u00ae formulation technology improving the oral bioavailability of cannabidiol in healthy subjects","volume":"24","author":"Knaub","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.jiph.2026.103264_bib264","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/jncimonographs\/lgad030","article-title":"Patient out-of-pocket costs for cannabis use during cancer treatment","volume":"2024","author":"Lapen","year":"2024","journal-title":"JNCI Monogr"},{"key":"10.1016\/j.jiph.2026.103264_bib265","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1111\/bcp.14038","article-title":"A systematic review of cannabidiol dosing in clinical populations","volume":"85","author":"Millar","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiph.2026.103264_bib266","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar","year":"2018","journal-title":"Front Pharm"},{"key":"10.1016\/j.jiph.2026.103264_bib267","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/17425255.2020.1754793","article-title":"Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials","volume":"16","author":"Santos","year":"2020","journal-title":"Expert Opin Drug Metab & Toxicol"},{"issue":"4","key":"10.1016\/j.jiph.2026.103264_bib268","first-page":"287","article-title":"Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients","volume":"67","author":"Matsuzawa","year":"2003","journal-title":"Circulation journal official journal Japanese Circulation Society"},{"key":"10.1016\/j.jiph.2026.103264_bib269","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjcard.2005.07.108","article-title":"Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients","volume":"97","author":"Newman","year":"2006","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.jiph.2026.103264_bib270","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.clinthera.2006.11.004","article-title":"Expanding options with a wider range of rosuvastatin doses","volume":"28","author":"Olsson","year":"2006","journal-title":"Clin Ther"},{"issue":"20","key":"10.1016\/j.jiph.2026.103264_bib271","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jiph.2026.103264_bib272","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity: mechanistic insights and clinical implications","volume":"124","author":"Ward","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jiph.2026.103264_bib273","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jiph.2026.103264_bib274","first-page":"253","article-title":"Lipid-altering efficacy and safety of simvastatin 80 mg\/day: worldwide long-term experience in patients with hypercholesterolemia","volume":"10","author":"Davidson","year":"2000","journal-title":"Nutr Metab Cardiovasc Dis NMCD"},{"issue":"2","key":"10.1016\/j.jiph.2026.103264_bib275","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00002512-199710020-00006","article-title":"Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients","volume":"10","author":"Langtry","year":"1997","journal-title":"Drugs & Aging"},{"issue":"23","key":"10.1016\/j.jiph.2026.103264_bib276","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jiph.2026.103264_bib277","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMc1614112","article-title":"Pediatric drug formulations - unintended consequences of legislation","volume":"376","author":"Probst","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2026.103264_bib278","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.1994.00420070047005","article-title":"Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group","author":"Chrysant","year":"1994","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jiph.2026.103264_bib279","unstructured":"DRUGS.COM. 2025b. Lisinopril price guide [Online]. Available: \u3008https:\/\/www.drugs.com\/price-guide\/lisinopril\u3009 [Accessed January 22, 2025]."},{"key":"10.1016\/j.jiph.2026.103264_bib280","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2165\/00003495-200059050-00012","article-title":"Lisinopril: a review of its use in congestive heart failure","volume":"59","author":"Simpson","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.jiph.2026.103264_bib281","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1124\/dmd.119.086397","article-title":"An extensively humanized mouse model to predict pathways of drug disposition and drug\/drug interactions, and to facilitate design of clinical trials","volume":"47","author":"Henderson","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jiph.2026.103264_bib282","article-title":"New strategy for drug discovery by large-scale association analysis of molecular networks of different species","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiph.2026.103264_bib283","doi-asserted-by":"crossref","DOI":"10.17776\/csj.806343","article-title":"The in vitro effect of 5-FU and Tamoxifen Chemotherapeutics on penthose phosphate pathway enzymes","author":"Temel","year":"2021","journal-title":"Cumhur Sci J"},{"issue":"11","key":"10.1016\/j.jiph.2026.103264_bib284","first-page":"5304","article-title":"Tamoxifen and 5-fluorouracil in breast cancer: modulation of cellular RNA","volume":"43","author":"Benz","year":"1983","journal-title":"Cancer Res"},{"key":"10.1016\/j.jiph.2026.103264_bib285","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184524","article-title":"Real-world evaluation of universal germline screening for cancer treatment-relevant pharmacogenes","volume":"13","author":"Hutchcraft","year":"2021","journal-title":"Cancers"},{"issue":"36","key":"10.1016\/j.jiph.2026.103264_bib286","doi-asserted-by":"crossref","first-page":"12866","DOI":"10.1021\/ja9029768","article-title":"Inhibitory substrate binding site of human indoleamine 2,3-dioxygenase","volume":"131","author":"Lu","year":"2009","journal-title":"J Am Chem Soc"},{"issue":"4","key":"10.1016\/j.jiph.2026.103264_bib287","first-page":"405","article-title":"Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development","volume":"56","author":"Cummings","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jiph.2026.103264_bib288","article-title":"From thalidomide to rational molecular glue design for targeted protein degradation","author":"Oleinikovas","year":"2023","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jiph.2026.103264_bib289","doi-asserted-by":"crossref","DOI":"10.1021\/acs.chemrestox.4c00069","article-title":"Vivo and in vitro induction of cytochrome P450 3A4 by thalidomide in humanized-liver mice and experimental human hepatocyte HepaSH cells","author":"Uehara","year":"2024","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.jiph.2026.103264_bib290","doi-asserted-by":"crossref","DOI":"10.1038\/s42004-019-0172-x","article-title":"Crystal structure of the mitochondrial protein mitoNEET bound to a benze-sulfonide ligand","volume":"2","author":"Geldenhuys","year":"2019","journal-title":"Commun Chem"},{"issue":"11","key":"10.1016\/j.jiph.2026.103264_bib291","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1210\/en.2015-1367","article-title":"Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells","volume":"156","author":"Sbiera","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.jiph.2026.103264_bib292","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-017-0092-6","article-title":"Effect of mitochondrial uncouplers niclosamide ethanolamine (NEN) and oxyclozanide on hepatic metastasis of colon cancer","volume":"9","author":"Alasadi","year":"2018","journal-title":"Cell Death & Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib293","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bbrc.2020.09.071","article-title":"Niclosamide activates the AMP-activated protein kinase complex containing the \u03b22 subunit independently of AMP","volume":"533","author":"Suzuki","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jiph.2026.103264_bib294","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1096\/fasebj.31.1_supplement.780.4","article-title":"Niclosamide blocks glucagon phosphorylation of serine 552 on \u03b2-catenin leading to decrease target genes expression and improve glucose metabolism via PKA signalling pathway","volume":"31","author":"Chowdhury","year":"2017","journal-title":"FASEB J"},{"key":"10.1016\/j.jiph.2026.103264_bib295","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0014-2999(79)90049-9","article-title":"Antimyoclonic action of clonazepam: the role of serotonin","volume":"60","author":"Hwang","year":"1979","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jiph.2026.103264_bib296","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.0c00274","article-title":"Comprehensive investigation of metabolic changes occurring in the rat brain hippocampus after fluoxetine administration using two complementary in vivo techniques: solid phase microextraction and microdialysis","author":"Boyaci","year":"2020","journal-title":"ACS Chem Neurosci"},{"issue":"10","key":"10.1016\/j.jiph.2026.103264_bib297","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1073\/pnas.68.10.2325","article-title":"Chlorpromazine and dopamine: conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs","volume":"68","author":"Horn","year":"1971","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.jiph.2026.103264_bib298","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cbi.2009.05.014","article-title":"Metabolic activation of the phenothiazine antipsychotics chlorpromazine and thioridazine to electrophilic iminoquinone species in human liver microsomes and recombinant P450s","volume":"181","author":"Wen","year":"2009","journal-title":"Chem-Biol Interact"},{"key":"10.1016\/j.jiph.2026.103264_bib299","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15257-1","article-title":"Ca2+-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids","volume":"11","author":"Grein","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jiph.2026.103264_bib300","article-title":"The chiral target of daptomycin is the 2R,2's stereoisomer of phosphatidylglycerol","author":"Moreira","year":"2021","journal-title":"Angew Chem"},{"key":"10.1016\/j.jiph.2026.103264_bib301","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.02071-15","article-title":"Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for \u03b2-lactam\u2013daptomycin synergy","volume":"60","author":"Berti","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jiph.2026.103264_bib302","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.celrep.2013.01.027","article-title":"The impact of aminoglycosides on the dynamics of translation elongation","volume":"3","author":"Tsai","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.jiph.2026.103264_bib303","first-page":"10","article-title":"Elucidation of teicoplanin interactions with drug targets related to COVID-19","author":"Azam","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.jiph.2026.103264_bib304","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.968148","article-title":"Investigations of nitazoxanide molecular targets and pathways for the treatment of hepatocellular carcinoma using network pharmacology and molecular docking","volume":"13","author":"Khan","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiph.2026.103264_bib305","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.800","article-title":"Synthesis, in vitro bioassays, and computational study of heteroaryl nitazoxanide analogs","volume":"9","author":"Ahmed","year":"2021","journal-title":"Pharmacol Res & Perspect"},{"key":"10.1016\/j.jiph.2026.103264_bib306","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fmicb.2020.00025","article-title":"Subinhibitory concentrations of fusidic acid may reduce the virulence of S. aureus by down-regulating sara and saers to reduce biofilm formation and \u03b1-toxin expression","volume":"11","author":"Liu","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jiph.2026.103264_bib307","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.1c00195","article-title":"Rv0684\/fusA1, an essential gene, is the target of fusidic acid and its derivatives in mycobacterium tuberculosis","author":"Singh","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.jiph.2026.103264_bib308","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2020.101920","article-title":"Drug repurposing: fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations","volume":"121","author":"Akinpelu","year":"2020","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jiph.2026.103264_bib309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-019-0384-9","article-title":"Minocycline impairs TNF-\u03b1-induced cell fusion of M13SV1-Cre cells with MDA-MB-435-pFDR1 cells by suppressing NF-\u03baB transcriptional activity and its induction of target-gene expression of fusion-relevant factors","volume":"17","author":"Weiler","year":"2019","journal-title":"Cell Commun Signal"},{"issue":"Pt6","key":"10.1016\/j.jiph.2026.103264_bib310","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/brain\/awf133","article-title":"Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis","volume":"125","author":"Brundula","year":"2002","journal-title":"Brain a J Neurol"},{"key":"10.1016\/j.jiph.2026.103264_bib311","doi-asserted-by":"crossref","first-page":"12334","DOI":"10.1021\/acs.inorgchem.9b01882","article-title":"Organoruthenated nitroxoline derivatives impair tumor cell invasion through inhibition of cathepsin B activity","volume":"58","author":"Mitrovi\u0107","year":"2019","journal-title":"Inorg Chem"},{"key":"10.1016\/j.jiph.2026.103264_bib312","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-59492-4","article-title":"Integrative proteomic and functional analyses provide novel insights into the action of the repurposed drug candidate nitroxoline in AsPC-1 cells","volume":"10","author":"Veschi","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiph.2026.103264_bib313","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1185\/03007995.2010.486301","article-title":"Diclofenac: an update on its mechanism of action and safety profile","volume":"26","author":"Gan","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jiph.2026.103264_bib314","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184385","article-title":"Development and challenges of diclofenac-based novel therapeutics: targeting cancer and complex diseases","volume":"14","author":"Amanullah","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.jiph.2026.103264_bib315","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1067\/mai.2001.114239","article-title":"Desloratadine: a new, nonsedating, oral antihistamine","volume":"107","author":"Geha","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jiph.2026.103264_bib316","first-page":"15","article-title":"Speciation analysis highlights the interactions of auranofin with the cytoskeleton proteins of lung cancer cells","author":"Kupiec","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jiph.2026.103264_bib317","doi-asserted-by":"crossref","first-page":"35728","DOI":"10.18632\/oncotarget.16113","article-title":"Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jiph.2026.103264_bib318","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25215186","article-title":"Molecular targets of cannabidiol in experimental models of neurological disease","volume":"25","author":"Silvestro","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jiph.2026.103264_bib319","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.jiph.2026.103264_bib320","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.drudis.2017.03.001","article-title":"Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins","volume":"22","author":"Banfi","year":"2017","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.jiph.2026.103264_bib321","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/BJ20100056","article-title":"Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril","volume":"428","author":"Watermeyer","year":"2010","journal-title":"Biochem J"},{"key":"10.1016\/j.jiph.2026.103264_bib322","article-title":"Role of artificial intelligence in revolutionizing drug discovery","author":"Rehman","year":"2024","journal-title":"Fundam Res"},{"key":"10.1016\/j.jiph.2026.103264_bib323","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/metabo13050625","article-title":"High-throughput screening of natural product and synthetic molecule libraries for antibacterial drug discovery","volume":"13","author":"Ayon","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.jiph.2026.103264_bib324","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/ijp.ijp_860_22","article-title":"Translational research: bridging the gap between preclinical and clinical research","volume":"54","author":"Mahalmani","year":"2022","journal-title":"Indian J Pharm"},{"key":"10.1016\/j.jiph.2026.103264_bib325","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics13060528","article-title":"Deciphering the antibacterial mechanisms of 5-fluorouracil in Escherichia coli through biochemical and transcriptomic analyses","volume":"13","author":"Zhang","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.jiph.2026.103264_bib326","first-page":"13","article-title":"Innovative strategies in drug repurposing to tackle intracellular bacterial pathogens","author":"Lorente-Torres","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.jiph.2026.103264_bib327","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015493","article-title":"The combination of antibiotic and non-antibiotic compounds improves antibiotic efficacy against multidrug-resistant bacteria","volume":"24","author":"Xiao","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jiph.2026.103264_bib328","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2025.1493915","article-title":"Beyond antibiotics: exploring multifaceted approaches to combat bacterial resistance in the modern era: a comprehensive review","volume":"15","author":"Yarahmadi","year":"2025","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187603412600136X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187603412600136X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:08:20Z","timestamp":1781698100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187603412600136X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":328,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S187603412600136X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103264","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Old drugs, new lifelines: An update on drug repurposing against multidrug-resistant Acinetobacter baumannii","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"103264"}}